Foundayo

Foundayo is the brand name for orforglipron, a once-daily GLP-1 tablet developed by Eli Lilly and approved by the MHRA in August 2026 for weight management in the UK. It works on the same GLP-1 receptor as Wegovy and Mounjaro, but it is a small non-peptide molecule designed to be taken as an ordinary tablet.

Both are once-daily GLP-1 tablets, but the molecules are different. Wegovy Tablets contain semaglutide, which must be taken on an empty stomach with a 30-minute wait. Foundayo contains orforglipron, which is absorbed with or without food, so it can be taken at any time of day with no waiting. Your pharmacist will recommend the one that fits your history and routine.

It activates the GLP-1 receptor, which regulates appetite. It signals your brain that you are full and slows down stomach emptying, so you feel satisfied with less food and experience fewer cravings — the same mechanism as the injectable GLP-1 treatments.

In the ATTAIN-1 trial, adults with obesity taking the highest studied dose of orforglipron once daily lost on average around 11–12% of their body weight over 72 weeks, compared with roughly 2% on placebo. Trial results are averages — individual response varies, which is why every patient is reviewed monthly.

Yes — it is a new medicine, and like all new medicines it is under additional monitoring by the MHRA (you will see a black triangle ▼ on the leaflet). ▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk). The safety profile seen in trials is broadly the same as other GLP-1 treatments: mostly digestive side effects during dose escalation.

No needles, no sharps bin, no fridge, and no timing rules — one tablet a day, whenever suits you. The trade-off is that the injectable treatments have shown larger average weight loss in trials, so your pharmacist will talk you through what matters most for you.

Yes. Foundayo is licensed for weight management in people without diabetes who have a BMI over 30 (or 27 with weight-related health conditions such as high blood pressure).

Take one tablet once a day, at any time of day, with or without food. Swallow it whole with water — do not break, crush or chew it. Try to take it at roughly the same time each day so it becomes a habit.

No. This is one of the main practical differences from Wegovy Tablets — Foundayo has no food or water restrictions.

0.8mg (Month 1), 2.5mg (Month 2), 5.5mg (Month 3), then 9mg, 14.5mg and 17.2mg as needed. Each step lasts a minimum of 30 days, and steps beyond 5.5mg depend on how you respond and how well you tolerate the medicine. Many patients settle at a dose below the maximum.

Take it as soon as you remember that day. If it is already the next day, skip the missed dose and take your next tablet as normal. Never take two tablets on the same day to catch up.

No. The tablet must be swallowed whole.

No. Each step lasts at least 30 days, but you can stay on a step for longer. If you are losing weight steadily and tolerating the dose, your pharmacist may keep you there — the highest dose is not the goal for everyone.

Possibly — but because orforglipron is a different molecule, there is no direct dose-for-dose switch. Anyone moving from an injection starts Foundayo at 0.8mg and titrates up under pharmacist review. If you are still in the early months of an injectable, your pharmacist will usually recommend finishing that titration first.

Some medicines raise the level of orforglipron in your body — in particular strong CYP3A4 inhibitors (such as clarithromycin, itraconazole or ritonavir) and OATP1B1 inhibitors (such as ciclosporin or gemfibrozil). If you take one of these, your maximum dose is 9mg. Always list every medicine you take in your consultation so your pharmacist can check.

No. Nausea is the most commonly reported side effect, but for many it is mild and occurs mainly during dose escalation, settling as your body adjusts. Eating smaller meals and avoiding fatty foods helps manage it.

The side-effect profile is broadly the same as the injectable GLP-1 treatments — nausea, constipation, diarrhoea and vomiting, mostly during dose escalation. Constipation was reported a little more often with orforglipron in trials, so keep your fluid and fibre intake up.

Some patients feel tired in the first few weeks as their calorie intake drops significantly. Ensuring you eat enough protein, stay hydrated, and don't drastically cut calories helps maintain energy levels.

Orforglipron slows stomach emptying, which can reduce how well an oral contraceptive is absorbed, particularly in the weeks after starting and after each dose increase. Your pharmacist will advise on additional precautions. Foundayo must not be taken during pregnancy.

Yes, because it keeps food in your stomach longer, some patients experience acid reflux. Avoid lying down immediately after eating, eat smaller portions, and avoid spicy or acidic foods to prevent this.

Rare risks include pancreatitis and gallstones. If you feel severe abdominal pain radiating to your back, stop the medication and seek medical help immediately. These are uncommon but important to be aware of.

It is not prescribed during pregnancy or breastfeeding, or if you have a personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome. It is never combined with another GLP-1 medicine. A history of pancreatitis needs careful review. Your full medical history is checked before any prescription is issued.

No. Store the tablets at room temperature in the original bottle and carton. No fridge, no cold chain.

By standard tracked delivery in discreet, unbranded packaging. Because the tablets don't require refrigeration, there is no cold-chain packaging or signed-for temperature handling to worry about.

Yes — keep the tablets in their original bottle in your hand luggage, away from heat. No cool bag needed. Ask us for a travel letter if you'd like one for airport security.

Many patients notice reduced appetite within the first few weeks, but meaningful weight change is tracked over months rather than days — particularly as the dose escalates through the six-step ladder.

Yes — Foundayo's starting doses are the lowest-priced GLP-1 treatment on Caremacy. The full per-dose pricing is shown in the table above. Your exact price depends on the dose your prescriber recommends and whether you choose Subscribe & Save.

Not yet. NICE is assessing orforglipron for NHS use with guidance expected later in 2026. Caremacy offers private access with pharmacist review typically within 24 hours.

We will move you to a "Maintenance Plan," likely lowering your dose gradually to help you maintain your weight loss without regaining. This is a critical phase we support you through.

Yes. Caremacy is a UK-registered pharmacy regulated by the GPhC (General Pharmaceutical Council). We source Foundayo through authorised UK supply channels with full batch traceability.

Every consultation receives individual review by a qualified prescriber, who verifies whether Foundayo is clinically appropriate based on your health profile. Prescriptions are not approved automatically.

Yes. Available clinical-support channels are explained during the consultation and before treatment begins.

Caremacy is a GPhC-registered UK pharmacy. Every prescription is dispensed by our clinical team and patients receive direct pharmacist support.

Your health data is protected under UK GDPR and strict medical confidentiality rules. We use encrypted systems for all personal and health information. We never sell data or share it for marketing. Discretion and privacy are built into every step.

Tell us straight away through your dashboard or your monthly check-in so your pharmacist can review it. Because Foundayo is under additional monitoring, we also report suspected side effects to the MHRA Yellow Card scheme — and you can report directly at yellowcard.mhra.gov.uk.